Study of Efficacy and Safety of CTL019 in Adult ALL Patients
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and
safety of CTL019 in adult patients with r/r B-cell ALL. The study will have the following
sequential phases: Screening, Pre-Treatment, Treatment and Primary Follow-up, Secondary
Follow-up (Relapse Follow-up) and Survival Follow-up. The total duration of the primary
follow-up is 1 year from cell infusion. Safety will be assessed until the end of the
treatment and primary follow-up phase.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania